Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism

Yorvipath (palopegteriparatide) is FDA approved for hypoparathyroidism. Ascendis Pharma's review period for TransCon PTH extended to August 14, 2024.


Related News

Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism

Yorvipath (palopegteriparatide) is FDA approved for hypoparathyroidism. Ascendis Pharma's review period for TransCon PTH extended to August 14, 2024.

© Copyright 2024. All Rights Reserved by MedPath